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esponsibility of InstAbstract The aims of the present study were to estimate the afﬁnity between 3,5-(E)-bis(3-methoxy-4-
hydroxybenzal)-4-piperidinone hydrochloride (C0818) and heat shock protein 90 (Hsp90) and to
investigate the inhibitory effects of this compound on Hsp90 ATPase activity. Fluorescence spectroscopy
was used to examine the afﬁnity between varying concentrations of C0818 and Hsp90, N-Hsp90, M-
Hsp90 and C-Hsp90. Fluorescence intensities were recorded in the range of 290–510 nm at 293, 303 and
310 K, respectively. A colorimetric assay for inorganic phosphate (based on the formation of a
phosphomolybdate complex and the subsequent reaction with malachite green) were used to examine
the inhibitory effects of C0818 on Hsp90 ATPase activity. The equilibrium dissociation constant KD value
of C0818 was found to be 23.41270.943 μmol/L. The interaction between C0818 and Hsp90 was driven
mainly by electrostatic interactions. C0818 showed the strongest afﬁnity with C-Hsp90. These results
conclusively demonstrate the inhibitory activity of C0818 on the activity of Hsp90 ATPase.
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Heat shock protein 90 (Hsp90) is an ATP-dependent cellular
chaperone responsible for maintaining the stability and activity of
a number of client proteins involved in cell signaling, proliferation
and survival1,2. Recent studies have shown that Hsp90 is a key
protein for oncogenesis and malignancy, and an emerging target
for cancer therapeutics3–6. Hsp90 inhibitors can simultaneously
inhibit multiple signaling pathways that cancer cells depend on for
their growth and proliferation. Since Hsp90 inhibitors have
signiﬁcant potential as antitumor agents, the discovery of Hsp90
inhibitors with new chemical scaffolds is relevant to advances in
cancer chemotherapy.
The chaperoning of most Hsp90 client proteins is regulated by a
dynamic cycle driven by ATP binding to Hsp90 and subsequent
hydrolysis of the protein7. The intrinsic ATPase activity of Hsp90 is
essential to this activity. Inhibition of the ATPase activity of Hsp90
leads to antitumor activity in vitro and in vivo8,9.
Curcumin is an active ingredient of the plant turmeric (Curcuma
longa). In our previous work10, we found that curcumin is a lead
compound in the search for new kinds of Hsp90 inhibitors. We thus
synthesized a series of derivatives, some of which showed lead-like
properties and were found to be more active than curcumin in Hsp90
inhibition and antitumor action11,12. In the present paper, we have
investigated a novel curcumin derivative, 3,5-(E)-bis(3-methoxy-4-
hydroxybenzal)-4-piperidinone hydrochloride (C0818), for its interac-
tion with Hsp90 and its inhibitory effect on the activity of Hsp90
ATPase.2. Materials and methods
2.1. Materials and reagents
Bacterial strains and plasmids were provided by Prof. Lianru Zhang
from School of Life Science, Xiamen University, China. C0818 was
designed and synthesized by our laboratory (Fig. 1). Ni2þ–nitrilotria-
cetic acid (NTA) agarose was purchased from General Electric (Little
Chalfont, Buckinghamshire, England). ATP was purchased from
Sigma–Aldrich (St. Louis, MO, USA). Geldanamycin (GA) was
purchased from Shanghai Sangon Biological Engineering (Lot. No.
XP0806132012J, Shanghai, China). A stock solution of Hsp90, which
was expressed and puriﬁed by our laboratory, was prepared in a
10 mmol/L PBS buffer with a pH 7.4, and the applied concentration
was ﬁxed at 5.0 μmol/L. C0818 was dissolved in 5% DMSO for
ﬂuorescence measurements. The water used in the experiments was
thrice-distilled using a Milli-Q Biocel system (Millipore, Bedford, MA,
USA). All other reagents were of analytical reagent grade.2.2. Cloning, expression, and puriﬁcation Hsp90
Yeast Hsp90 recombinant plasmid (Hsp90-PET-28a) was used to
transform the target constructs of Hsp90 to express in the strainFigure 1 Chemical structure of C0818.Escherichia coli BL21(DE3). The monoclonal cell was picked and
cultured in lysogeny broth (LB) at 37 1C. Various constructs of
Hsp90, including histidine (his)-tagged yeast full-length Hsp90
(1–732, 90 kDa), the N-terminal domain of Hsp90 (N-Hsp90, 1–
236, 25 kDa), the middle domain of Hsp90 (M-Hsp90, 272–617,
40 kDa) and the C-terminal domain of Hsp90 (C-Hsp90, 629–732,
15 kDa), were induced by IPTG (isopropyl β-D-1-thiogalactopyr-
anoside) and expressed in bacterial strains and puriﬁed by
Ni2þ-NTA (nitrilotriacetic acid) and gel ﬁltration13.
2.3. Fluorescent measurements
Samples were excited at 280 nm and ﬂuorescence intensities were
recorded in the range of 290–500 nm at 293, 303 and 310 K,
respectively, using a Cary Eclipse (Varian, Palo Alto, CA, USA).
Fluorometric titration experiments were performed in 2.0 mL of
5.0 μmol/L Hsp90 solution (10 mmol/L PBS buffer, pH 7.6) with
successive additions of C0818 solution (in 0.2% DMSO) from 5.0 to
50 μmol/L. All tests were performed in triplicate14.
2.4. Hsp90 ATPase activity assay
The reaction was performed in 100 μL of assay buffer (6 mmol/L
MgCl2, 20 mmol/L KCl and 100 mmol/L Tris–HCl, pH 7.4)
containing 0.4 μmol/L Hsp90, 1 mmol/L ATP and different con-
centrations of C0818 or GA or vehicle (DMSO) and incubated at
310 K for 3 h. At the end of the incubation, the ATPase activity of
Hsp90 were assessed by malachite green reagent (0.0812% w/v
malachite green, 2.32% w/v polyvinyl alcohol and 5.72% w/v
ammonium molybdate in 6 mol/L HCl, and argon water mixed in a
ratio of 2:1:1:2, v/v/v/v). Cultures were analyzed in triplicate at an
absorbance of 620 nm13. The kinetic analysis of the Hsp90
ATPase activity was carried out using a nonlinear regression ﬁt
of the experimental points to the Michaelis–Menten equation. To
obtain Km and V values, the Eadie–Hofstee linear transformation
(V against V/[s]) was used, with the slope¼Km and the intercept
on the x axis¼V/Km13.
2.5. Statistical analysis
All data were analyzed with two-sided unpaired t-test in the
GraphPad software package for Windows (Prism version 5.0) and
Origin8.5 software. Values are expressed as means of triplicate or
duplicate experiments.3. Results
3.1. The interaction between C0818 and Hsp90
3.1.1. C0818 quenched the intrinsic ﬂuorescence of Hsp90
The binding of C0818 to Hsp90 was characterized by ﬂuorescence
quenching. At excitation wavelength of 280 nm, the interaction was
examined with ﬂuorescence spectrum from 290 to 510 nm. His-tagged
Hsp90 displayed maximal ﬂuorescence at 334 nm. When Hsp90 was
incubated with increasing concentrations of C0818, the ﬂuorescence
intensity gradually decreased with a slight blue shift of λem (Fig. 2A).
The dissociation constants (KD) is calculated by the equation:
ΔF ¼ F0F ¼ Fmax Q½ =KD þ Q½  ð1Þ
where F0 is the steady-state ﬂuorescence intensity of Hsp90, F is
the ﬂuorescence intensity of Hsp90 in presence of C0818 at
Figure 2 C0818 physically binds to Hsp90. (A) Quenching effect of C0818 (0–50 μmol/L) on Hsp90 endogenous ﬂuorescent in a concentration-
dependent manner. The maximal ﬂuorescence displayed at 334 nm. (B) The change trend of Hsp90 ﬂuorescence intensity with C0818
concentration. (C) Stern–Volmer plot for the binding of C0818 with Hsp90. (D) Lineweaver–Burk plot for the binding of C0818 with Hsp90.
Table 1 Dissociation constant KD values of C0818 and
geldanamycin (GA).
Compound Fmax KD (μmol/L) R2
GA 546.1677.92 24.3970.79 0.999
C0818 329.9375.79 23.4170.94 0.999
Table 3 The binding constant KA and the binding number n
of C0818 and GA.
Compound KA (L/mol) n R
2
GA 2.88 105 1.1470.04 0.986
C0818 1.04 107 1.4470.05 0.989
Interaction between C0818 and Hsp90 93different concentrations, and [Q] is the concentration of C0818.
The titration curves for Hsp90 yields estimated dissociation
constants (KD) of C0818 for Hsp90, which is of
23.4170.94 μmol/L (Fig. 2B), indicating that C0818 quenched
the intrinsic ﬂuorescence of Hsp90 and that there was a binding
interaction between them15 (Table 1).
3.1.2. Quenching constant and quenching rate constant
The quenching process can be analyzed by Stern–Volmer equation:
F0=F ¼ 1þ Ksv Q½  ¼ 1þ Kτ0q Q½  ð2Þ
where F0, F and [Q] means the same as in Eq. (1), KSV is the
Stern–Volmer quenching constant in static quenching, Kq is the
quenching rate constant, and τ0 is endogenous ﬂuorescence life-
time value of biological macromolecules16, which generally is
108 s. Ksv and Kq were obtained from the slope of F0/F plotted
against [Q] (Fig. 2C) and the results are listed in Table 2.Table 2 The Stern–Volmer quenching constant Ksv and bimolecular
Compound Kq (L/mol/s)
GA (7.6770.44) 1012
C0818 (1.4970.12) 1013The maximum dynamic collisional quenching constant of all
kinds of quenching agent with biopolymers is 2.0 1010 L/mol/s,
the quenching rate constant Kq of C0818 was greater than
2.0 1010 L/mol/s, indicating that the quenching effect of C0818
on intrinsic ﬂuorescence of Hsp90 is not due to molecules collision
in dynamic quenching, but due to the formation of complex in
static quenching17.
3.1.3. Number of binding sites and constant
Static quenching complies with the Lineweaver–Burk equation18:
Lg F0–F=F ¼ Lg K þ n Lg Q½  ð3Þ
where F0, F and [Q] means the same as in Eq. (1), KA is the
apparent binding constant, and n is the binding site. KA and n were
obtained from the intercept and slope of lgF0 –F/F plotted against
lg[Q] (Fig. 2D), respectively, and the results are listed in Table 3.quenching constant Kq of C0818 and GA.
Ksv (L/mol) R
2
(7.6770.44) 104 0.968
(1.4970.12) 105 0.943
Yingjuan Fan et al.943.1.4. Thermodynamic parameters
Over the temperature ranges examined and when the thermodynamic
enthalpy change (ΔHθ) did not vary signiﬁcantly, van't Hoff's equation
was used to obtain the values of ΔHθ and entropy change (ΔSθ):
Ln KD1=KD2 ¼ΔHθ 1=T l–1=T2
 
=R ð4Þ
ΔGθ ¼ΔHθ–TΔSθ ¼RT LnKD ð5Þ
where R is the thermodynamic gas constant and the value is 8.314 J/
mol/K, T is thermodynamic temperature, KD is corresponding dis-
sociation constants at different temperatures, ΔGθ is Gibbs free energy
change. Fluorescence intensities were recorded in the range of
290–510 nm at 293, 303 and 310 K, respectively (Fig. 3).
The thermodynamic enthalpy change (ΔHθ), entropy change(ΔSθ)
and free energy change (ΔGθ) of C0818–Hsp90 binding were also
calculated from the ﬂuorescent spectrum, the results are listed in
Table 4. The negative enthalpy change and positive entropy change
suggest that electrostatic interaction predominated in stabilizing the
C0818–Hsp90 complex19.Figure 3 Quenching effect of C0818 (0–50 μmol/L) on Hsp90 endog
Table 4 Dissociation constant KD and thermodynamic parameters o
Compound T (K) KD (μmol/L) R2
GA 293 18.6370.79 0.999
303 22.4270.65 0.999
310 24.3970.80 0.999
C0818 293 39.1370.91 0.999
303 46.4471.72 0.999
310 53.4472.28 0.998
Figure 4 Synchronous ﬂuorescence spectra of C0818 (0–50In order to further determine the interaction type between
C0818 and Hsp90, a synchronous ﬂuorescence method was used
to study the impact of C0818 on Hsp90 conformation.3.1.5. Impact of C0818 on Hsp90 conformation
Tyrosine (Tyr) and tryptophan (Trp) are the main source of protein
ﬂuorescence. When the D-value (Δλ) between excitation and
emission wavelengths was stabilized at 15 or 60 nm, the synchro-
nous ﬂuorescence provided the characteristic information of Tyr or
Trp residues.
When Δλ was 15 or 60 nm, increasing concentrations of
C0818 led to a dramatic decrease in ﬂuorescence intensity, but
the ﬂuorescence peak position of Tyr or Trp residues remained
the same (Fig. 4), indicating that the microenvironment of Tyr or
Trp residues did not change after binding, and that the hydro-
phobic microenvironment did not obviously decrease. These
results imply that the conformation of Tyr or Trp of Hsp90 did
not change.enous ﬂuorescent at different temperatures (293, 303 and 310 K).
f C0818 and GA at different temperatures.
ΔGθ (kJ/mol) ΔHθ (kJ/mol) ΔSθ (J/mol/K)
26.5370.11 11.2072.42 52.3278.00
26.9770.07
27.3770.08
24.7270.06 12.9670.74 40.2772.45
25.1370.09
25.3570.11
μmol/L) with Hsp90. (A) Δλ ¼ 15 nm; (B) Δλ ¼ 60 nm.
Figure 5 Quenching effect of C0818 (0–50 μmol/L) on endogenous ﬂuorescent of N-Hsp90, M-Hsp90 and C-Hsp90.
Table 5 Dissociation constant KD of C0818 and GA.
Interaction Fmax KD (μmol/L) R2
N-Hsp90–GA 221.2274.91 5.8470.61 0.991
M-Hsp90–GA 158.2071.68 42.1370.80 0.999
C-Hsp90–GA 67.9170.63 36.7270.64 0.999
N-Hsp90–C0818 159.4873.15 38.1571.40 0.999
M-Hsp90–C0818 232.4673.46 24.5270.82 0.999
C-Hsp90–C0818 76.5171.35 13.5170.68 0.998
Figure 6 The inhibition rate of Hsp90 ATPase activity under
different concentrations of C0818 (0–200 μmol/L).
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The domain of Hsp90 involved in binding C0818 was determined by
constructing three truncation mutants: N-Hsp90, M-Hsp90 and
C-Hsp90, corresponding to its ATP-binding domain, its co-chaperone
binding domain and its dimerization domain. The ﬂuorescence
intensity of C-Hsp90, but not N-Hsp90 or M-Hsp90, was the most
obviously quenched with increasing concentrations of C0818, indicat-
ing that C0818 may interact with the C-terminal domain (Fig. 5). The
dissociation constant KD values are listed in Table 5.3.2. C0818 inhibits the ATPase activity of Hsp90
To characterize the inhibition of Hsp90 by C0818 binding, a
colorimetric assay for inorganic phosphate was used to measure the
inhibitory effect of C0818 on the ATPase activity of Hsp90. This assay
is based on the formation of a phosphomolybdate complex and a
subsequent reaction with malachite green. When the concentration of
ATP was 1 mmol/L, the IC50 values of C0818 and GA were 120.74
and 0.41 μmol/L, respectively. Fig. 6 demonstrates the inhibition of
Hsp90 ATPase activity by C0818. GA is a potent antiproliferativeagent but is not an ideal clinical agent due to its marked hepatotoxicity
and narrow therapeutic window9. C0818, a small-molecule inhibitor,
may have potential as a therapeutic agent with improved pharmaco-
logical properties compared to GA.4. Discussion
Quenching of the ﬂuorescence from a macromolecule can be classiﬁed
as static quenching or dynamic quenching. In static quenching, the
stability of new complexes of quenching agent and ﬂuorescent material
results in the decrease of the quenching constant of ﬂuorescence. In
dynamic quenching, the excited state molecules of quenching agent
and ﬂuorescent material collide with each other, resulting in energy
transfer20.
Our data suggest that C0818 is an Hsp90 inhibitor. Compared with
the known inhibitor GA, C0818 has a novel scaffold unrelated to that
of any other known Hsp90 inhibitor. Spectroscopic methods were used
to study the interaction between C0818 and full-length Hsp90,
N-Hsp90, M-Hsp90 and C-Hsp90. From the binding energy and
dissociation constants, we demonstrated that C0818 is an inhibitor of
Hsp90 and that it binds to the C-terminal dimerization domain of
Hsp90. The quenching effect of C0818 on Hsp90 intrinsic ﬂuorescence
can thus be classiﬁed as static quenching. The thermodynamic
parameters and the synchronous ﬂuorescence suggest that electrostatic
interactions predominate in stabilizing the C0818–Hsp90 complex.
C0818 inhibits the ATPase activity of Hsp90, so the binding of
C0818 inhibits the catalysis of ATP hydrolysis. The binding of Hsp90
pockets arrests the catalytic cycle of Hsp90 in the ADP-bound
conformation. The afﬁnity-based screen showed that C0818 binds to
Hsp90, therefore conﬁrming the interaction between Hsp90 and
C0818. In the assay measuring ATPase activity of Hsp90, C0818
demonstrated dose-dependent inhibition of the ATPase activity of
Hsp90. As expected, the positive control GA also showed dose-
dependent inhibition in this system.Acknowledgments
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